Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968466 | 0.86 | NOTUM (0.39) | DHODHS1PR1HDAC4HDAC2HDAC8 | |
| SCHEMBL7967160 | 0.85 | CYP11B1 (0.37) | FPR2CYP11B2PRMT5WDR77GPR55 | |
| SCHEMBL7968628 | 0.78 | — | — | |
| SCHEMBL7972402 | 0.78 | MMP12 (0.32) | — | |
| SCHEMBL7968235 | 0.74 | CTSD (0.34) | CYP11B2S1PR1HDAC4HDAC2HDAC8 | |
| SCHEMBL7984718 | 0.72 | CHRNA1 (0.42) | PTGS2 | |
| SCHEMBL7983353 | 0.72 | CHRNA1 (0.42) | PTGS2 | |
| SCHEMBL6932927 | 0.72 | CHRNA1 (0.42) | PTGS2 | |
| SCHEMBL6026628 | 0.71 | MEN1 (0.37) | PTGS2NOTUM | |
| SCHEMBL7966664 | 0.70 | HCAR2 (0.46) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019029-B2 | Skin whiteners containing hydroxytetronic acid derivatives | THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT | 2006-03-28 | — | — | US | disclosed |
| US-20020141956-A1 | Skin whiteners containing hydroxytetronic acid derivatives | THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT | 2002-10-03 | — | — | US | disclosed |
| US-6265436-B1 | ANTIINFLAMMATORY AGENTS | OXIS THERAPEUTICS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141956-A1 | Skin whiteners containing hydroxytetronic acid derivatives | TYR, PPP6C, CYP26A1 | FPR2 1183/4885PTGS2 1612/4885CYP11B2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.